| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 13712 | 2012 |
| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 9587 | 2015 |
| Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 8792 | 2015 |
| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 3998 | 2017 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2597 | 2018 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1638 | 2015 |
| Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses PC Rodriguez, DG Quiceno, J Zabaleta, B Ortiz, AH Zea, MB Piazuelo, ... Cancer research 64 (16), 5839-5849, 2004 | 1397 | 2004 |
| Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase DH Munn, MD Sharma, JR Lee, KG Jhaver, TS Johnson, DB Keskin, ... Science 297 (5588), 1867-1870, 2002 | 1303 | 2002 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1290 | 2016 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004, 2015 | 1283 | 2015 |
| Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes DH Munn, MD Sharma, D Hou, B Baban, JR Lee, SJ Antonia, JL Messina, ... The Journal of clinical investigation 114 (2), 280-290, 2004 | 1115 | 2004 |
| Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ... The lancet oncology 18 (1), 31-41, 2017 | 999 | 2017 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 927 | 2018 |
| Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ... Nature communications 5 (1), 5241, 2014 | 917 | 2014 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924, 2017 | 853 | 2017 |
| Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ... Cancer cell 33 (5), 853-861. e4, 2018 | 807 | 2018 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 796 | 2021 |
| Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study S Gettinger, L Horn, D Jackman, D Spigel, S Antonia, M Hellmann, ... Journal of Clinical Oncology 36 (17), 1675-1684, 2018 | 687 | 2018 |
| All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients N Mirza, M Fishman, I Fricke, M Dunn, AM Neuger, TJ Frost, RM Lush, ... Cancer research 66 (18), 9299-9307, 2006 | 668 | 2006 |
| Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study S Antonia, SB Goldberg, A Balmanoukian, JE Chaft, RE Sanborn, A Gupta, ... The lancet oncology 17 (3), 299-308, 2016 | 655 | 2016 |
